Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.54 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 6/20 | 0.50 |
| ▸ | CNR1 | P21554 | 4/20 | 0.50 |
| ▸ | TERT | O14746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13181137 | 0.93 | ALDH1A1 (0.59) | ALDH1A1MAPTMAPK1KDM4EGAA | |
| SCHEMBL12069745 | 0.87 | MAPT (0.54) | ALDH1A1MAPTMAPK1KDM4EGAA | |
| SCHEMBL19648765 | 0.87 | MAPT (0.69) | ALDH1A1MAPTMAPK1KDM4EGAA | |
| SCHEMBL1735497 | 0.86 | ALDH1A1 (0.74) | ALDH1A1MAPTMAPK1KDM4EGAA | |
| SCHEMBL6443035 | 0.84 | ALDH1A1 (0.51) | ALDH1A1MAPTMAPK1KDM4EGAA | |
| Hydrochloric Acid SCHEMBL8046149 | 0.83 | ALDH1A1 (0.70) | ALDH1A1MAPTMAPK1KDM4EGAA | |
| Hydrochloric Acid SCHEMBL8046146 | 0.83 | ALDH1A1 (0.70) | ALDH1A1MAPTMAPK1KDM4EGAA | |
| SCHEMBL13181094 | 0.83 | ALDH1A1 (0.50) | ALDH1A1MAPTMAPK1KDM4EGAA | |
| SCHEMBL15741279 | 0.83 | ALDH1A1 (0.54) | ALDH1A1MAPTMAPK1KDM4EGAA | |
| SCHEMBL1972710 | 0.80 | ALDH1A1 (0.67) | ALDH1A1MAPTMAPK1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1440390-A | Substituted diamine derivatives as motilin antagonists | ORTHO MCNEIL PHARM INC (US) | 2003-09-03 | — | — | CN | claimed |
| EP-3728238-A1 | SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS | Nodthera Limited (GB) | 2020-10-28 | — | — | EP | disclosed |
| EP-3567029-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | Lantheus Medical Imaging, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-2631980-B1 | NON-AQUEOUS ELECTROLYTE SOLUTION | DAIKIN IND LTD (JP) | 2017-10-11 | — | — | EP | disclosed |
| EP-2664619-B1 | Purine derivatives as tools for screening anti-Alzheimer compounds | MANROS THERAPEUTICS (FR) | 2017-07-12 | — | — | EP | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-1467974-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS GNRH ANTAGONISTS | SOD CONSEILS RECH APPLIC (FR) | 2007-08-15 | — | — | EP | disclosed |
| CN-1440390-A | Substituted diamine derivatives as motilin antagonists | ORTHO MCNEIL PHARM INC (US) | 2003-09-03 | — | — | CN | disclosed |
| EP-1294695-A2 | SUBSTITUTED DIAMIDE DERIVATIVES USEFUL AS MOTILIN ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001085694-A2 | SUBSTITUTED DIAMIDE DERIVATIVES USEFUL AS MOTILIN ANTAGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | ALDH1A1 617/4885MAPT 2813/4885MAPK1 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.